Scienture Holdings, INC 8-K filings

Scienture Holdings, Inc. announced the resignation of CFO Eric Sherb and the appointment of Co-CEO Dr. Narasimhan Mani as Interim CFO.

Scienture Holdings reported a 449% year-over-year revenue increase to $56,000 and secured $11 million in non-dilutive debt financing.

Scienture Holdings, Inc. has posted a revised investor presentation to its website, containing forward-looking statements about projects, financial performance, and growth opportunities.

Scienture Holdings, Inc. has entered into a $11 million secured note purchase agreement with Streeterville Capital, LLC to fund working capital and product development.

Scienture Holdings, Inc. filed an 8-K announcing the posting of a revised investor presentation to its website and plans for investor meetings.

Scienture Holdings, Inc. stockholders approved director elections, an equity plan increase, a potential future stock offering, and a reverse stock split, but rejected a significant increase in authorized shares.

Scienture Holdings, Inc. has increased its at-the-market equity offering program to an aggregate of up to $150 million, enhancing its capital raising flexibility.

Scienture Holdings, Inc. announced an increase in its common stock offering capacity to an aggregate of $9,592,009 under its existing equity distribution agreement.

Scienture Holdings, Inc. amended employment agreements for its Co-Chief Executive Officers, increasing base salaries and enhancing severance benefits.

Scienture Holdings, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, triggering a 180-day grace period to regain compliance.

Scienture Holdings, Inc. secured a new $3.91 million senior secured promissory note from Streeterville Capital, LLC, yielding $3.5 million in net proceeds, primarily used to repay an existing $2.66 million defaulted loan.

Scienture Holdings, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of voting stock.

Scienture Holdings, Inc. amended its convertible debentures with Arena Investors, revising the conversion price to $2.4861 per share and facilitating a full conversion of outstanding debt into common stock.

Scienture Holdings, Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to sell up to $9.2 million of common stock through an at-the-market offering.

Scienture Holdings, Inc. announced the closing of a registered direct offering, raising approximately $3.87 million through the sale of 3,225,000 common shares at $1.20 per share.

Scienture Holdings, Inc. announced it has secured approximately $1.2 million in bridge funding through a common stock issuance, part of a larger $3 million capital raise, to support upcoming product commercial launches and pipeline development.

Scienture Holdings, Inc. has entered into new indemnification agreements with its directors and officers to provide comprehensive protection against legal expenses and liabilities, aiming to attract and retain highly qualified individuals.

Scienture Holdings reports the termination of a purchase agreement, receipt of a Nasdaq delisting notice due to minimum bid price non-compliance, and a leadership transition with the resignation of the CEO and President and the appointment of co-CEOs.

Scienture Holdings, Inc. sells its Healthcare IT and Wholesale Operations subsidiaries to Tollo Health, Inc. for $5 million to streamline operations and focus on its specialty pharma business.

Scienture Holdings, Inc. announces a consulting agreement with Draper, Inc. for investor relations and business development, and the FDA approval of Arbli™ (losartan potassium) Oral Suspension.

Scienture Holdings, Inc. announces the appointment of Eric Sherb as Chief Financial Officer and reports the results of its 2024 Annual Meeting of Stockholders.

Scienture Holdings, through its subsidiary, has entered into an agreement with Kindeva Drug Delivery to exclusively commercialize REZENOPY (naloxone HCl) Nasal Spray 10mg in the U.S., a critical step in combating the opioid epidemic.

Scienture Holdings, Inc. reports the voluntary resignations of two directors, Narasimhan Mani and Prashant Patel, and a subsequent reduction in the board size from seven to five members.

Scienture Holdings received a notice from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, putting its listing status at risk.

Scienture Holdings has finalized a $12 million private placement of convertible debentures and a $50 million equity line of credit agreement to bolster its financial position.

Scienture Holdings converted all outstanding Series X Preferred Stock into 6,826,713 shares of common stock, bringing the total outstanding common shares to 8,576,795.

Scienture Holdings, Inc. has released an investor presentation to be used in meetings with analysts and potential investors.

TRxADE Health, Inc. has officially changed its name to Scienture Holdings, Inc., and its stock now trades under the ticker symbol SCNX on the Nasdaq Stock Market, effective September 23, 2024.

TRxADE Health, Inc. has finalized its merger with Scienture, Inc., a pharmaceutical company, in an all-stock transaction valued at $103 million.

TRxADE Health has declared a special cash dividend of $1.50 per share, payable to shareholders of record on July 19, 2024, using proceeds from the sale of its web-based market platform assets.